Oppenheimer Initiates Coverage On City Therapeutics with Outperform Rating, Announces Price Target of $46

Benzinga · 1d ago
Oppenheimer analyst Joseph Thomas initiates coverage on City Therapeutics (NASDAQ:CTY) with a Outperform rating and announces Price Target of $46.